|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Detection of disseminated pancreatic cells by amplification of cytokeratin-19 with quantitative RT-PCR in blood,bone marrow and peritoneal lavage of pancreatic carcinoma patients显示文摘AIM: To evaluate the diagnostic potential of cytokeratin-19 (CK-19) mRNA for the detection of disseminated tumor cells in blood, bone marrow and peritoneal lavage in patients with ductal adenocarcinoma of the pancreas. METHODS: Sixty-eight patients with pancreatic cancer (n = 37), chronic pancreatitis (n = 16), and non-pan- creatic benign surgical diseases (n = 15, control group) were included in the study. Venous blood was taken preoperatively, intraoperatively and at postoperative d 1 and 10. Preoperative bone marrow aspirates and peritoneal lavage taken before mobilization of the tumor were analyzed. All samples were evaluated for disseminated tumor cells by CK-19-specific nested-PCR and quantitative fluorogenic RT-PCR. RESULTS: CK-19 mRNA expression was increased in 24 (64%) blood samples and 11 (30%) of the peritoneal lavage samples in the patients with pancreatic cancer. In 15 (40%) of the patients with pancreatic cancer, disseminated tumor cells were detected in venous blood and bone marrow and/or peritoneal lavage. In the peritoneal lavage, the detection rates were correlated with the tumor size and the tumor differentiation. CK-19 levels were increased in pT3/T4 and moderately/poorly differentiated tumors (G2/G3). Pancreatic cancer patients with at least one CK-19 mRNA-positive sample showed a trend towards shorter survival. Pancreatic cancerpatients showed significantly increased detection rates of disseminated tumor cells in blood and peritoneal lavage compared to the controls and the patients with chronic pancreatitis. CONCLUSION: Disseminated tumor cells can be detected in patients with pancreatic ductal adenocar- cinoma by CK-19 fluorogenic RT-PCR. In peritoneal lavage, detection rate is correlated with tumor stage and differentiation. In the clinical use, CK-19 is suitable for the distinction between malignant and benign pancreatic disease in combination with other tumor-specific markers. | Katrin Hoffmann Christiane Kerner Wolfgang Wilfert Marc Mueller Joachim Thiery Johann Hauss Helmut Witzigmann | 2007 | World Journal of Gastroenterology2007，13，2： | 20 |
| 2 | The amazing potential of fungi:50 ways we can exploit fungi industrially显示文摘Fungi are an understudied,biotechnologically valuable group of organisms.Due to the immense range of habitats that fungi inhabit,and the consequent need to compete against a diverse array of other fungi,bacteria,and animals,fungi have developed numerous survival mechanisms.The unique attributes of fungi thus herald great promise for their application in biotechnology and industry.Moreover,fungi can be grown with relative ease,making production at scale viable.The search for fungal biodiversity,and the construction of a living fungi collection,both have incredible economic potential in locating organisms with novel industrial uses that will lead to novel products.This manuscript reviews fifty ways in which fungi can potentially be utilized as biotechnology.We provide notes and examples for each potential exploitation and give examples from our own work and the work of other notable researchers.We also provide a flow chart that can be used to convince funding bodies of the importance of fungi for biotechnological research and as potential products.Fungi have provided the world with penicillin,lovastatin,and other globally significant medicines,and they remain an untapped resource with enormous industrial potential. | Kevin D.Hyde Jianchu Xu Sylvie Rapior Rajesh Jeewon Saisamorn Lumyong Allen Grace T.Niego Pranami D.Abeywickrama Janith V.S.Aluthmuhandiram Rashika S.Brahamanage Siraprapa Brooks Amornrat Chaiyasen K.W.Thilini Chethana Putarak Chomnunti Clara Chepkirui Boontiya Chuankid Nimali I.de Silva Mingkwan Doilom Craig Faulds Eleni Gentekaki Venkat Gopalan Pattana Kakumyan Dulanjalee Harishchandra Hridya Hemachandran Sinang Hongsanan Anuruddha Karunarathna Samantha C.Karunarathna Sehroon Khan Jaturong Kumla Ruvishika S.Jayawardena Jian-Kui Liu Ningguo Liu Thatsanee Luangharn Allan Patrick G.Macabeo Diana S.Marasinghe Dan Meeks Peter E.Mortimer Peter Mueller Sadia Nadir Karaba N.Nataraja Sureeporn Nontachaiyapoom Meghan O’Brien Watsana Penkhrue Chayanard Phukhamsakda Uma Shaanker Ramanan Achala R.Rathnayaka Resurreccion B.Sadaba Birthe Sandargo Binu C.Samarakoon Danushka S.Tennakoon Ramamoorthy Siva Wasan Sriprom T.S.Suryanarayanan Kanaporn Sujarit Nakarin Suwannarach Thitipone Suwunwong Benjarong Thongbai Naritsada Thongklang Deping Wei S.Nuwanthika Wijesinghe Jake Winiski Jiye Yan Erandi Yasanthika Marc Stadler | 2019 | Fungal Diversity2019，，4： | 3 |
| 3 | Cachexia and pancreatic cancer: Are there treatment options?显示文摘Cachexia is frequently described in patients with pancreatic ductal adenocarcinoma(PDAC)and is associated with reduced survival and quality of life.Unfortunately,the therapeutic options of this multi-factorial and complex syndrome are limited.This is due to the fact that,despite extensive preclinical and clinical research,the underlying pathological mechanisms leading to PDAC-associated cachexia are still not fully understood.Furthermore,there is still a lack of consensus on the definition of cachexia,which complicates the standardization of diagnosis and treatment as well as the analysis of the current literature.In order to provide an efficient therapy for cachexia,an early and reliable diagnosis and consistent monitoring is required,which can be challenging especially in obese patients.Although many substances have been tested in clinical and preclinical settings,so far none of them have been proven to have a long-term effect in ameliorating cancer-associated cachexia.However,recent studies have demonstrated that multidimensional therapeutic modalities are able to alleviate pancreatic cancerassociated cachexia and ultimately improve patients’outcome.In this current review,we propose a stepwise and pragmatic approach to facilitate and standardize the treatment of cachexia in pancreatic cancer patients.This strategy consists of nutritional,dietary,pharmacological,physical and psychological methods. | Tara C Mueller Marc A Burmeister Jeannine Bachmann Marc E Martignoni | 2014 | World Journal of Gastroenterology2014，20，28： | 3 |
| 4 | Preoperative thrombocytosis predicts poor survival in patients with glioblastom a显示文摘 | AIf Giese Kathrin Mueller | 2007 | Neuro Oncol2007，9，3： | 1 |
| 5 | Donor evaluation, donor risks, donor outcome, and donor quality of life in adult-to-adult living donor liver transplantation显示文摘 | Andreas Pascher Igor M. Sauer Marc Walter Enrique Lopez-Haeninnen Tom Theruvath Antonino Spinelli Ruth Neuhaus Utz Settmacher Andrea R. Mueller Thomas Steinmueller Peter Neuhaus | 2002 | Liver Transplantation2002，，9： | 1 |
| 6 | Parental information, motivation, and adherence behaviors among children with sickle cell disease显示文摘 | Jean L. Raphael Ashley M. Butler Tiffany L. Rattler Marc A. Kowalkowski Brigitta U. Mueller Thomas P. Giordano | 2013 | Blood Cancer2013，，7： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员